Stockreport

INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]

INmune Bio Inc. - Common stock  (INMB) 
PDF Research and Development Expenses: Approximately $20.7 million for 2025, down from $33.2 million in 2024. General and Administrative Expenses: Approximately $10.3 mil [Read more]